Travere Therapeutics Inc (TVTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Travere Therapeutics Inc   (NASDAQ: TVTX)


Travere Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Travere Therapeutics Inc's ROI in the second quarter of 2026?
Travere Therapeutics Inc recorded a cumulative net loss of $-43 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -9.03%.

Within the Healthcare sector 198 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1833 to 2884.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 33.75 % 9.33 % -2.89 % -17.15 % -35.28 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 647 430 445 404 366
Return On Investment (TTM) -9.03 % -5.21 % -6.46 % -23.16 % -46.96 %
TVTX's Overall Ranking # 2884 # 1833 # 2395 # 2896 # 0
Seq. Investment Change TTM 17.12 % 4.01 % 3.4 % 6.19 % -4.26 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -43 -21 -26 -89 -169

TVTX Company Profile >> Back to TVTX Roi Comparisons >> See Annual TVTX Return On Investment



Return On Investment TVTX's Ranking
Within: No.
Industry # 67
Sector # 199
Overall # 2884

Return On Investment Statistics
High Average Low
36.12 %
-56.7 %
-1244.3 %
(Sep 30 2015)   (Jun 30 2014)



  News about Travere Therapeutics Inc Return on Investment ROI

Travere Therapeutics Submits sNDA to FDA for FILSPARI in IgA Nephropathy, While Stock Rallies on Market Confidence

March 11, 2024

Travere Therapeutics Aims for Full FDA Approval of FILSPARI in IgA Nephropathy as Stock Soars
Travere Therapeutics, a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, has recently submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking full approval for their drug FILSPARI (sparsentan) in the treatment of IgA Nephropathy (IgAN). This move comes after the company s successful acquisition of accelerated approval for FILSPARI in this indication, and marks a significant step towards providing a long-term treatment solution for patients suffering from this debilitating kidney disease.
IgA Nephropathy, often referred to as Berger s disease, is a chronic autoimmune kidney disorder characterized by the abnormal deposition of Immunoglobulin A (IgA) in the glomeruli, causing inflammation and progressive damage to the kidneys. It is estimated to affect millions of people worldwide, with limited treatment options currently available.





Financial Statements
Travere Therapeutics Inc's II. Quarter Investments $ 647 Millions TVTX's Balance sheet
Travere Therapeutics Inc's II. Quarter Income $ -35 Millions Quarterly TVTX's Income Statement
TVTX's Income by Division See TVTX's Income by Division


TVTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 445 393 611 530 653
Y / Y Investment Growth 13.2 % -35.62 % 15.19 % -18.71 % 26.76 %
Net Income in Millions -26 -322 -111 -278 -180
Y / Y Net Income Growth - - - - -
Annual Return On Investment -5.74 % -81.74 % -18.23 % -52.5 % -27.6 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TVTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TVTX's Competitors
Subscribers only: Roi for Travere Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for TVTX's Customers

Other Ratios
TVTX's Roa TVTX's Inventory Turnover Ratio TVTX's Growth Rates TVTX's Dividend Statistics
TVTX's Profitability Ratios TVTX's Asset Turnover Ratio TVTX's Dividend Growth
TVTX's Roe TVTX's Valuation Ratios TVTX's Financial Strength Ratios TVTX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:12:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.